Preference-based valuation of treatment attributes in haemophilia A using web survey
Introduction: Clinical trials have shown promising results for extended half-life factor VIII concentrates but little is known about individuals' valuation of haemophilia treatment attributes. Aim: To assess patient/caregiver and population valuation of treatment attributes of prophylactic regimens for people with severe haemophilia A. Methods: Members ≥16 years of the Swedish Haemophilia Society